PSORS4
MCID: PSR025
MIFTS: 25

Psoriasis 4 (PSORS4)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Psoriasis 4

MalaCards integrated aliases for Psoriasis 4:

Name: Psoriasis 4 57 12
Psoriasis Susceptibility 4 57 13
Psors4 57 12
Psoriasis 4, Susceptibility to 57

Classifications:



External Ids:

Disease Ontology 12 DOID:0111280

Summaries for Psoriasis 4

Disease Ontology : 12 A psoriasis that has material basis in variation in a region on chromosome 1q21.

MalaCards based summary : Psoriasis 4, also known as psoriasis susceptibility 4, is related to psoriasis and pustulosis of palm and sole. An important gene associated with Psoriasis 4 is PSORS4 (Psoriasis Susceptibility 4). The drugs Indirubin and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include skin and endothelial.

More information from OMIM: 603935 PS177900

Related Diseases for Psoriasis 4

Diseases in the Psoriasis family:

Psoriasis 1 Psoriasis 3
Psoriasis 2 Psoriasis 4
Psoriasis 5 Psoriasis 6
Psoriasis 7 Psoriasis 9
Psoriasis 8 Psoriasis 10
Psoriasis 11 Psoriasis 12
Psoriasis 13 Psoriasis 15

Diseases related to Psoriasis 4 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 12)
# Related Disease Score Top Affiliating Genes
1 psoriasis 11.8
2 pustulosis of palm and sole 10.6
3 psoriasis 1 10.4
4 ige responsiveness, atopic 10.1
5 psoriasis 3 10.1
6 psoriasis 2 10.1
7 dermatitis, atopic 10.1
8 dermatitis, atopic, 2 10.1
9 psoriatic arthritis 10.1
10 psoriasis 9 10.1
11 dermatitis 10.1
12 skin disease 10.1

Graphical network of the top 20 diseases related to Psoriasis 4:



Diseases related to Psoriasis 4

Symptoms & Phenotypes for Psoriasis 4

Clinical features from OMIM:

603935

Drugs & Therapeutics for Psoriasis 4

Drugs for Psoriasis 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Indirubin Investigational Phase 2 479-41-4
2 Antibodies Phase 2
3 Antibodies, Monoclonal Phase 2
4 Immunoglobulins Phase 2
5 Anti-Bacterial Agents Phase 2
6 Antibiotics, Antitubercular Phase 2
7
Dexamethasone Approved, Investigational, Vet_approved Early Phase 1 50-02-2 5743
8
Methotrexate Approved Early Phase 1 1959-05-2, 59-05-2 126941
9
leucovorin Approved Early Phase 1 58-05-9 143 6006
10
Dexamethasone acetate Approved, Investigational, Vet_approved Early Phase 1 1177-87-3
11
Folic acid Approved, Nutraceutical, Vet_approved Early Phase 1 59-30-3 6037
12 Folic Acid Antagonists Early Phase 1
13 Vitamin B9 Early Phase 1
14 Nucleic Acid Synthesis Inhibitors Early Phase 1
15 Vitamin B Complex Early Phase 1
16 Folate Early Phase 1
17 Antimetabolites, Antineoplastic Early Phase 1
18 Antimetabolites Early Phase 1
19 BB 1101 Early Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Randomized, Double-Blind, , Placebo Controlled, 18 Week Study To Evaluate the Efficacy of Adjuvant 9-cis-β-Carotene Rich Powder of the Alga Dunaliella Bardawil in Subjects With Plaque Type Psoriasis Treated by Narrow Band UVB Therapy Withdrawn NCT01121081 Phase 3 Alga Dunaliella Bardawil;Placebo
2 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of MEDI-522, a Humanized Monoclonal Antibody to Integrin Alpha V Beta 3, Administered by Subcutaneous Injection to Adults With Plaque Psoriasis Completed NCT00192517 Phase 2 MEDI-522
3 Mechanistic Study of Indigo Naturalis in Treating Psoriasis: Local or Systemic Manipulation of Inflammation and Induction of Immunoregulation Completed NCT02088281 Phase 2 Indigo naturalis extract in oil ointment
4 Study of Topical Application of AS101 for the Treatment of Psoriasis Withdrawn NCT00788424 Phase 2 AS101 Cream
5 Cyclosporine in the Pharmacotherapy of Psoriasis Withdrawn NCT00377325 Phase 2 Cyclosporine
6 Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study Unknown status NCT02644044 Early Phase 1 Intrathecal methotrexate

Search NIH Clinical Center for Psoriasis 4

Genetic Tests for Psoriasis 4

Anatomical Context for Psoriasis 4

MalaCards organs/tissues related to Psoriasis 4:

41
Skin, Endothelial

Publications for Psoriasis 4

Articles related to Psoriasis 4:

(show top 50) (show all 59)
# Title Authors PMID Year
1
Association of skin barrier genes within the PSORS4 locus is enriched in Singaporean Chinese with early-onset psoriasis. 38 8
18787534 2009
2
Peptidoglycan recognition proteins Pglyrp3 and Pglyrp4 are encoded from the epidermal differentiation complex and are candidate genes for the Psors4 locus on chromosome 1q21. 38 8
16362825 2006
3
Co-localization of susceptibility loci for psoriasis (PSORS4) and atopic dermatitis (ATOD2) on human chromosome 1q21. 38 8
16912508 2006
4
Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. 38 8
16163348 2005
5
Characterization of the loricrin (LOR) gene as a positional candidate for the PSORS4 psoriasis susceptibility locus. 38 8
15598222 2004
6
Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. 38 8
11348461 2001
7
Loss-of-function mutations in filaggrin gene associate with psoriasis vulgaris in Chinese population. 8
22407025 2012
8
FLG mutation p.Lys4021X in the C-terminal imperfect filaggrin repeat in Japanese patients with atopic eczema. 8
19663875 2009
9
Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. 8
19169253 2009
10
Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. 8
19169255 2009
11
Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. 8
10577939 1999
12
Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1. 8
9886260 1999
13
Mycosis fungoides with spongiosis: A potential diagnostic pitfall. 38
30989664 2019
14
A case of secondary IgA nephropathy accompanied by psoriasis treated with secukinumab. 38
30941695 2019
15
Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. 38
30887876 2019
16
Interpretation of Nondiagnostic Vulvar Biopsies. 38
29271860 2018
17
Endogenous endophthalmitis and osteomyelitis associated with interleukin 17 inhibitor treatment for psoriasis in a patient with diabetes. 38
28667056 2017
18
Health-related Quality of Life in Children and Adolescents with Psoriasis: A Systematic Review and Meta-analysis. 38
27983745 2017
19
NOD-like receptor signaling and inflammasome-related pathways are highlighted in psoriatic epidermis. 38
26976200 2016
20
A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis. 38
26556603 2015
21
Opposing Effects of Zac1 and Curcumin on AP-1-Regulated Expressions of S100A7. 38
26633653 2015
22
Analysis of protein-protein interaction between late cornified envelope proteins and corneodesmosin. 38
25078048 2014
23
Inflammatory bowel diseases: Current problems and future tasks. 38
25133045 2014
24
Failure to find evidence for deletion of LCE3C and LCE3B genes at PSORS4 contributing to psoriasis susceptibility in Tunisian families. 38
24485035 2014
25
Associations between the major histocompatibility complex class I chain-related gene A transmembrane (MICA-TM) polymorphism and susceptibility to psoriasis and psoriatic arthritis: a meta-analysis. 38
23974432 2014
26
Regulation of late cornified envelope genes relevant to psoriasis risk by plant-derived cyanidin. 38
24393842 2014
27
Control of late cornified envelope genes relevant to psoriasis risk: upregulation by 1,25-dihydroxyvitamin D3 and plant-derived delphinidin. 38
23839497 2013
28
Blaschko-linear manifestations of polygenic inflammatory diseases: analysis of 17 cases. 38
24185002 2013
29
The link between enthesitis and arthritis in psoriatic arthritis: a switch to a vascular phenotype at insertions may play a role in arthritis development. 38
22863575 2013
30
Worldwide population distribution of the common LCE3C-LCE3B deletion associated with psoriasis and other autoimmune disorders. 38
23594316 2013
31
Cumulative life course impairment: identifying patients at risk. 38
23796811 2013
32
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. 38
23205325 2012
33
HLA-C, CSTA and DS12346 susceptibility alleles confer over 100-fold increased risk of developing psoriasis: evidence of gene interaction. 38
21412248 2011
34
Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. 38
21332464 2011
35
New psoriasis susceptibility genes: momentum for skin-barrier disruption. 38
21494239 2011
36
Gene from a psoriasis susceptibility locus primes the skin for inflammation. 38
21148126 2010
37
Depression in adult dermatology outpatients. 38
21205547 2010
38
Deletion of LCE3C and LCE3B genes at PSORS4 does not contribute to susceptibility to psoriatic arthritis in German patients. 38
19439430 2010
39
Association of psoriasis to PGLYRP and SPRR genes at PSORS4 locus on 1q shows heterogeneity between Finnish, Swedish and Irish families. 38
18643845 2009
40
Comparison of the Expression Profile of JunB, c-Jun, and S100A8 (Calgranulin A) in Psoriasis Vulgaris and Guttate Psoriasis. 38
20548852 2009
41
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. 38
18369459 2008
42
Etanercept treatment for children and adolescents with plaque psoriasis. 38
18199863 2008
43
[Changes of ultrastructure and p-53 protein expression on the peripheral blood lymphocytes of patients with vulgar form of psoriasis after balneal therapy in resort "nunisi"]. 38
15988091 2005
44
Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. 38
15757824 2005
45
Analysis of 6 genetic loci for disease susceptibility in psoriatic arthritis. 38
15517637 2004
46
[Study of the association between HLA-DQA1 alleles and environmental factors in psoriasis]. 38
12667357 2002
47
Evidence for differential S100 gene over-expression in psoriatic patients from genetically heterogeneous pedigrees. 38
12384771 2002
48
Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. 38
12056961 2002
49
A prospective survey of pediatric dermatology clinic patients in Kuwait: an analysis of 10,000 cases. 38
10027990 1999
50
Seasonal variation of DNA damage and repair in patients with non-melanoma skin cancer and referents with and without psoriasis. 38
9539978 1998

Variations for Psoriasis 4

Expression for Psoriasis 4

Search GEO for disease gene expression data for Psoriasis 4.

Pathways for Psoriasis 4

GO Terms for Psoriasis 4

Sources for Psoriasis 4

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....